Effects of Altered Neural Input and Botulinum Toxin on Finger and Wrist Passive Properties in Chronic Hemiparetic Stroke

Benjamin I Binder-Markey[1,2,3,4] DPT, PhD, Wendy M Murray[1,2,3,4,5], PhD, *Julius P.A. Dewald[1,2,3] PT, PhD

[1]Department of Biomedical Engineering, Northwestern University, Evanston, IL
[2]Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL
[3]Department of Physical Medicine and Rehabilitation Science, Northwestern University, Chicago, IL
[4]Shirley Ryan AbilityLab, Chicago, IL
[5] Research Service, Edward Hines Jr., VA Hospital, Hines, IL

*Coresponding Author:
Julius PA Dewald, PT, PhD
645 N. Michigan Ave
Suite 1100
Chicago, IL 60611
Phone: (312) 908-6788
Email:j-dewald@northwestern.edu

ABSTRACT

Background and Purpose: Following a hemiparetic stroke, prolonged altered motor neuron inputs may drive passive mechanical changes within muscle that further amplify brain injury induced motor impairments, reducing optimal recovery. However, due to confounding factors, i.e. muscle hypertonicity and spasticity, and the use of botulinum neurotoxin (BoNT), chemical denervation to reduce their expression, there is no consensus on how altered neural inputs following a stroke affect muscle passive mechanical properties or the extent to which these properties ultimately limit functional recovery. Therefore, the objective of this study is to quantify muscle passive biomechanical properties following chronic hemiparetic stroke and BoNT.

Methods: Passive torques about the wrist and metacarpophalangeal (MCP) joints were quantified in both hands of 34 individuals with chronic hemiparetic stroke. Participants' hand impairments ranged from severe to mild with a subset who previously received BoNT injections. Torques were quantified with subjects in a sleep or near-sleep state, mitigating muscle hyperactivity. EMGs were continuously monitored to ensure no muscle activity during data collection.

Results: Participants who previously received BoNT injections demonstrated significantly greater passive flexion torques about their paretic wrist and fingers as compared to those who never received BoNT. As a result, only the group who received BoNT demonstrated significant decreases in passive MCP extension.

Conclusions: The results of our thorough investigation of *in vivo* passive elastic torques at the wrist and fingers in chronic hemiparetic stroke contrast with the increased stiffness and decreased passive ROM observed clinically and in many previous studies. We highlight the need to effective address both stroke-induced muscle hyperactivity and BoNT treatment history as confounds. We conclude that loss of hand function post-stroke is predominantly due to motor impairments post stroke. Adverse effects of BoNT warrant consideration in future studies and rehabilitation interventions.

1 INTRODUCTION

Following a hemiparetic stroke, induced damage to corticofugal motor (i.e., corticospinal and corticobulbar) pathways results in an increased reliance on indirect contralesional corticoreticulospinal pathways[1-5]. Increased reliance on these indirect pathways alters neural input to spinal motor neurons resulting in motor impairments such as weakness[6-8], loss of independent joint control[9-13], and motor neuron hyperactivity manifesting as hypertonicity and spasticity (i.e., hyperactive stretch reflexes)[14-18]. This altered motor drive, over time, may change the mechanical structure of muscle, further amplifying brain injury induced motor impairments. Additionally, botulinum neurotoxin (BoNT) chemical denervation, widely used to treat muscle hypertonicity and spasticity[19-21], may also alter structural properties of muscle.[22-26] One particularly detrimental sequelae of these structural muscle adaptations are that muscles can become increasingly stiff, making movement progressively more difficult preventing individuals from achieving optimal recovery.

There is not a clear consensus regarding how prolonged exposure to altered neural inputs following a stroke affects muscle structure and its passive mechanical properties. Previous studies quantifying muscle adaptions following a stroke have demonstrated decreased fascicle lengths[27-29], often accompanied by increased joint torques and stiffness[7,27,28,30-34] which has been interpreted as evidence of muscle contractures and mechanical property changes following a stroke. However, there is also conflicting evidence that passive mechanical properties are not different between the paretic and non-paretic limbs of stroke survivors.[30,35]

The varied results that previous studies report may be a consequence of differences in which abnormal muscle hyperactivity, a confounding factor, was effectively controlled among these studies. Abnormal muscle hypertonicity and spasticity increases the chances of muscle activity,

even in conditions intended to be "passive" or "relaxed". For example, some studies utilized continuous motion to collect passive torques.[7,32,33] However, even low constant velocities have been demonstrated to elicit hyperactive stretch reflexes that increase paretic finger torques by ≥30%.[8] In some studies, EMGs were not recorded, leaving it unclear whether data collection occurred in the absence of muscle activity.[27,35] In other cases, passive torques were estimated rather than directly measured; muscles were active and measured EMGs were used in a dynamic analytical model to decompose active torques from passive torques.[7,31,33] Finally, while pre-stretching attenuates hyperactive motoneurons and the stretch reflex,[36] few studies discuss whether stretching prior to data collection was utilized.[7,27,32,33,35] These methodological differences among previous studies obfuscate our understanding of muscle passive properties following chronic stroke.

An additional confounding variable that is neither discussed nor reported in the context of the inclusion/exclusion criteria in previous studies is the potential long term effect of BoNT. BoNT chemical denervation is included in neurological clinical practice guidelines for treatment of adult spasticity,[19] and is commonly used to treat muscle hypertonicity and spasticity.[19-21] Presumably, the BoNT induced reduction of muscle tone[20] improves function by increasing range of motion (ROM) and reducing overall motor impairment. Yet, evidence of these beneficial effects is limited and is based largely on subjective clinical assessments of tone and ROM without demonstrated improvements in either function or quality of life.[21] In contrast, structural changes that include increased intramuscular connective tissue and passive mechanical stiffness have been demonstrated in murine muscles following BoNT injections, both acutely and chronically[22-26]. If the administration of BoNT imposes the same effects within human muscle, it is critical to

understand both how these structural changes are distinct from stroke-induced alterations and the extent to which the induced structural changes effect optimal recovery.

The overall objective of this study is to determine the extent to which muscle passive biomechanical properties change following stroke and with the administration of BoNT by comparing passive torques collected from both limbs of individuals with chronic hemiparetic stroke. We chose to study the muscles of the hand and wrist because they have the longest lasting and most severe impairments following a stroke[37-40] and are a frequent site of BoNT treatment. To evaluate the effects of altered neural inputs over a broad gradation, we recruited individuals with severe to mild hand impairments. Additionally, we explored potential long-term effects of chemical denervation following BoNT by including a subset of stroke participants with a history of BoNT treatment. Based on the prevailing findings of previous literature and the common clinical presentation of stiff, flexed wrist and finger postures following a stroke, the driving hypotheses for this work are: 1) passive torques of the paretic hand are greater than the non-paretic hand, 2) interlimb differences in joint torques are graded with severity of hand impairment and 3) paretic limbs with wrist and finger muscles that have been chemically denervated using BoNT have greater increases in passive torques than those that have not.

2 MATERIALS AND METHODS

2.1 Participants

An interdepartmental research database, the Clinical Neuroscience Research Registry from Northwestern University and the Shirley Ryan AbilityLab, was used to pre-screen individuals with chronic hemiparetic stroke based on set inclusion/exclusion criteria (Table 1). Prior clinical assessment of upper-limb impairment, as recorded in the registry, was used to recruit individuals

across a broad range of impairment levels. 38 individuals were initially enrolled, 28 of whom had never received BoNT injections (no-BoNT). Each of the 10 individuals who had previously received BoNT injections (BoNT-injected) received injections within the forearm flexor compartment. A single enrollee was subsequently excluded due to also having received BoNT injections in forearm extensor compartment. The 9 remaining individuals in this group were at least one year post-BoNT injection. The data from three additional enrollees (2, BoNT-injected group; 1, no-BoNT) were excluded from the analysis due to the inability to relax during testing, as determined by EMG activity (see section 2.5). The remaining 34 study participants were stratified into 3 groups by hand impairment using the Chedoke McMaster Stroke Assessment Hand Score (CMSA-HS)[41], administered at the time of testing by a single, trained and licensed physical therapist. CMSA-HS of 1-3 were considered severe impairments (n=16; of which 7 had BoNT-injections), 4-5 moderate impairments (n=9), and 6-7 mild impairments (n=9) (see Table 2). The 7 BoNT-injected participants had clinical scores (CMSA-HS, Modified Ashworth Scale (MAS)) that were not significantly different from those who had severe impairments and no history of BoNT (p=0.196 and p=0.158, respectively) (Table 2). Clinically relevant subject demographics were gathered from all participants in a brief questionnaire prior to data collection.

The study protocol was developed in compliance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Northwestern University. Participants gave informed consent prior to participation.

2.2 Experimental Set-up

A custom built device[42] was used to collect torques produced about the wrist and fingers. The device allows the experimenter to position the wrist and metacarpophalangeal (MCP) joints separately, in discrete 15° increments, while simultaneously collecting torques about each joint.

Participants were seated in an upright position with their hand secured in the device (Figure 1). The participant's arm was positioned comfortably at their side with the forearm parallel to the ground and palm facing medially; eliminating the effects of gravity in the plane of wrist and finger flexion and extension (Figure 1). The two distal finger joints were splinted, ensuring isolated wrist and MCP movements. Muscle activity was monitored throughout each trial using surface electrodes (16-channel Bagnoli EMG System, Delsys Inc., Boston, MA; 1000 x gain, 20-450 Hz bandpass) placed over 4 muscles; Flexor Digitorium Superficialis, Flexor Carpi Ulnaris, Extensor Digitorium Communis, and Extensor Carpi Radialis.

2.3 Muscle Hyperactivity Inhibition Protocol

Muscle hyperactivity was reduced and quieted during data collection by encouraging participants to sleep or be in a near-sleep state throughout the protocol. Decreased muscle hyperactivity in this relaxed state is hypothesized to be due to a reduction in reticulospinal tract activity resulting in decreased spinal motoneurons excitability and muscle hyperactivity allowing the muscle to be in a passive state[43-45].

The relaxed state was facilitated by creating a dark, relaxing atmosphere; relaxing videos or music was also played. Each session began with 10-15 minutes of stretching of the shoulder, elbow, wrist, and fingers. Participants were positioned in the device, the lights were turned off and a relaxing video or music was turned on; these conditions remained in effect throughout the remainder of the protocol. An additional 10 minutes of 90 second sustained stretches of the wrist and fingers were performed. These stretches accommodated the individual to the device, decreases in EMG activity and measured torques were observed at this point (Supplemental Figure 1).[36] The wrist and fingers were then allowed to move freely and rest at their equilibrium posture by unlocking the device's MCP and wrist restraints. At this equilibrium posture, three 15-second

baseline trials with no evidence of EMG activity were collected to zero the device and define passive EMG baseline.

2.4 Experimental Procedure

The protocol for each limb was completed on two separate days; data from the non-paretic hand was collected on the first day. Passive torques were collected from a maximum of 108 combinations of wrist and MCP joint postures, depending on individual participant's available ROM. Torques were collected at static postures. Wrist posture was randomly set in 15° increments between 60° of flexion and 60° of extension (9 wrist postures). One (BoNT-injected) had limited wrist extension in the paretic limb, and could only be positioned in 6 of the 9 postures. At each wrist posture, the MCP joints were positioned in full extension, moved to full flexion, and then moved back to full extension in static 15° increments. MCP ROM was determined by each subject's comfort level; the device's limits established the maximum possible ROM in this study. At each static posture, data was collected for 15 seconds and visually inspected. Trials for which there was evidence of muscle activity and corresponding torque deviations were discarded and repeated.

2.5 Data processing:

Raw torque and EMGs were collected and digitized at a sampling frequency of 1kHz. The torque and rectified EMG data were then digitally filtered using a zero-phase infinite impulse response 4th-order Butterworth low-pass filter with a 4Hz corner frequency.

The processed baseline trials (see Section 2.3) were used to set the torque offset and EMG threshold. Torque offset was defined to be the average torque measured during the three baseline trials. EMG threshold, EMG_t, was defined as:

$$EMG_t = \bar{x}_{EMG_base} + 3 \cdot \sigma_{EMG_base}$$

where $\bar{x}_{EMG_base}$ is the average of the three EMG baseline trials and σ_{EMG_base} is the average EMG standard deviation over the three baseline trials.

For each static trial (i.e., the torque produced in a single combination of wrist and MCP joint position), the processed torque and EMG data were divided into 1-second bins, resulting in 15 bins per trial. The average torque and EMG value were first calculated for each of the 15 bins. For a given 1-second bin in any trial, if the average EMG signal from any muscle exceeded EMG_t or if the torque deviated ≥ 5% from the mode across the entire trial, the bin was discarded. The average of the remaining bins within each trial were used to create the total torque versus wrist and MCP posture data set for each subject.

2.6 Analysis of Data

To determine the effect of hand (paretic vs. non-paretic), a generalized linear-mixed model analysis was completed in SPSS (v24.0 IBM Corp Armonk, NY). We analyzed measured MCP joint torque, wrist joint torque, and ROM of the MCP joints across all wrist angles of the participants within each group (severe BoNT-injected, severe no-BoNT, moderate, and mild). Across all analyses, the dependent variable was either torque or ROM and data were analyzed using four factors including participant, hand (paretic/non-paretic), MCP position, and wrist position. Participants were set as a random factor; all other factors were fixed factors.

To determine the effect of group (severe BoNT-injected, severe no-BoNT, moderate, and mild) on torque differences between the paretic and non-paretic hand, we completed a separate generalized linear-mixed model analysis. For each participant, differences in torques were calculated by subtracting non-paretic torque from paretic torque at each posture. When ROM was limited in the paretic hand, the difference was only calculated for postures achievable by both

paretic and non-paretic hands. Across this analysis, the dependent variable was torque difference (either MCP or wrist). Data were analyzed using four factors including subject (random effect), group, MCP, and wrist position. A post-hoc bonferonni pairwise comparison was performed to determine significant differences between groups.

3 DATA AVAILABILITY

The data sets used within this analysis are available by request from the authors.

4 RESULTS

4.1 Measured Total Passive Torque about the Wrist and MCP joints

At the MCP joints, significant differences ($p<0.05$) in passive torques were observed between paretic and non-paretic limbs in every group (Figure 2a). However, individuals who had received BoNT injections in their forearm muscles had significantly larger interlimb differences in MCP joint torques than individuals who had not undergone BoNT treatments ($p<0.05$ for all comparisons), regardless of impairment level (Figures 2b). Across all postures, the average difference in MCP joint torque between paretic and non-paretic limbs of the BoNT-injected group was +23.2 Ncm, with interlimb differences systematically increasing from 60° wrist flexion (+12.4 Ncm) to 60° wrist extension (+43.6 Ncm) (Figure 2b). For the no-BoNT groups, the small interlimb differences observed in the severely (average across all joint postures = +6.8 Ncm), moderately (average = +5.4 Ncm), and mildly (average = +1.6 Ncm) impaired groups were not significantly different from each other, and did not demonstrate the systematic increase with wrist extension observed in the BoNT-injected group.

The passive torques at the wrist replicated the fundamental observations at the MCP joints. Specifically, significant differences ($p<0.05$) in passive torques were observed between the paretic and non-paretic limbs in the BoNT-injected, severe, and moderate impairment groups (Figure 3a).

However, interlimb differences were significantly larger in the BoNT-injected group than in any of the impairment groups with no BoNT history (Figure 3b). Across all MCP postures, and among all subjects, the average difference in passive wrist joint torques between paretic and non-paretic limbs of the BoNT-injected group was +36.3 Ncm. This interlimb difference systematically increased from flexed MCP postures to extended MCP postures. Interlimb differences in wrist torques were at least five times smaller for the severely (+5.1 Ncm), moderately (+7.2 Ncm), and mildly (+1.1 Ncm) impaired no-BoNT groups. MCP posture had limited impact on the magnitude of the interlimb differences observed in the no-BoNT groups.

4.2 Impact on Range of motion

The BoNT-injected group had a significantly smaller range of passive MCP extension in the paretic hand compared to the non-paretic hand ($p < 0.001$). The average decrease in MCP extension across all wrist angles was 33°. For the 6 BoNT-injected participants who could attain 60° wrist extension in the paretic limb (see methods), the passive limit of MCP extension was an average of 68° less extended than the non-paretic limb (Figure 4a). In contrast, for the no-BoNT group with comparable clinical impairment scores, the passive limit of MCP extension was not significantly different between limbs ($p=0.360$) (Figure 4b).

5 DISCUSSION

The objective of this research was to evaluate if passive mechanical muscle properties are different after prolonged changes in neural input to the muscle, as the result of stroke, while minimizing and controlling for potential confounding factors of muscle hyperactivity and potential long-term side-effects of chemical denervation following BoNT injections. To this purpose, on a cohort of chronic hemiparetic stroke individuals with mild to severe hand impairments we tested

three hypotheses:1) passive torques of the paretic hand are greater than the non-paretic hand, 2) interlimb differences in joint torques are graded with severity of hand impairments and 3) limbs with wrist and finger muscles injected with BoNT have greater increases in passive joint torques than those that have not. Our most striking results were that individuals who had received BoNT injections in their forearm muscles had significantly larger interlimb differences in pasive joint torques than individuals who had not had BoNT injections (Figures 2 & 3). While significant interlimb differences in passive torques were observed in the groups who had not received BoNT injections, the differences were small and did not scale with impairment level (Figure 2b & 3b). Additionally, interlimb passive torque differences systematically increased with postures that lengthen the wrist and finger flexor muscles within the BoNT group only, (Fig 2b & 3b). These increases are consistent with both increased muscle stiffness at the site of BoNT injection and the fact that the loss of passive MCP extension became increasingly severe as the wrist was extended (Figure 4).

5.1 Origin of increased torques within BoNT-injected muscles

The increased flexion torques and decreased ROM we observed suggest that individuals who received BoNT injections experienced long lasting muscular property changes; the average time since our participants' last BoNT injection was over four years prior to the collection of this data (Table 2). Because we did not observe comparable torque increases in any of the no-BoNT groups, we conclude the observed differences are an effect of BoNT, not neural impairments post stroke. Previous animal studies demonstrate muscles have increased collagen content in the ECM following BoNT injections; increases were observed within 6 months and lasted the animal's lifespan.[22,23,26] The underlying mechanism of this increased collagen content is unknown. Because BoNT chemically denervates a muscle, it is thought that the resulting adaptation is similar to

traditional denervation. Denervated muscle has been shown to demonstrate increases in collagen content within a month after denervation[46-49] and a recent study comparing muscle treated with BoNT and a denervated muscle demonstrated similar patterns of progressive atrophy and collagen content increases (Richard L. Lieber, personal communication of unpublished data, 2019). Increases in collagen content are likely to cause increases in muscle stiffness.

5.2 Implications of BoNT use in the stroke populations

Our results suggest BoNT injections likely have a negative effect on the passive mechanics of muscle by substantially increasing the muscle's stiffness. As opposed to the increases in passive ROM that have been observed 1-2 months following BoNT injection, presumably due to induced paralysis that temporarily eliminates muscle hyperactivity,[50] we observed significant decreases in passive MCP extension within the BoNT-injected group, that was not observed in the other groups (Figure 4). Importantly, the deficits in passive ROM likely underestimate the extent that active ROM would be affected. With active finger extensor strength decreasing as much as 90%,[6-8] and increased torque generation necessary to extend the fingers due to the increased passive torques, we would expect even larger losses in active ROM. Further studies into the mechanism by which BoNT affects muscle are necessary to enhance our understanding of the long-term effects of BoNT on muscle structure and passive mechanics, especially after stroke.

5.3 Discrepancies from previous published work

Within our chort of individuals with chronic hemiparetic stroke who had never received BoNT, we observed only small interlimb differences in passive torque and no significant differences in passive ROM. Many previous studies have reported increased joint torques and muscle stiffness[7,27,28,30-34] following a stroke. Within this study, we took great care to reduce the

impact of muscle hyperactivity. We also analyzed participants who received BoNT separately. The inconsistencies between our results and previous studies may underscore the importance of considering these important confounding factors. Simple instructions to relax are likely not sufficient; many individuals with chronic stroke are unable to fully relax while awake due to motoneuron hyperexcitability, resulting in muscle hypertonicity. Decreasing hypertonicity of muscles may require significant reduction in reticulospinal tract activity. We addressed this confound via a thorough stretching protocol and encouraging participants to sleep during testing. We monitored muscle activity and observed its decrease during preparation for testing (Supplemental Figure 1).[43-45] These critical steps should be considered when attempting to quantify passive mechanical adaptations of muscles within any "spastic" population.

5.4 Study Limitations

A limitation to our study is that we are unable to discern how different mechanisms, such as atrophy (loss of contractile material), adaptations of muscle extra-cellular matrix (ECM), tendon compliance, or their combination may contribute to our results. Atrophy would likely cause a decrease in joint torques due to a loss of muscle mass. We estimated each subject's forearm volume (by measuring forearm length, wrist circumference, and maximum forearm circumference) and verified that there was no significant difference between arms using paired t-tests (severe BoNT-injected $p=0.245$, severe no-BoNT $p=0.244$, moderate $p=0.885$, mild $p=0.604$). In general, no study quantifying joint properties can distinguish between effects due to adapations in muscle architecture, ECM, or tendon compliance. Future studies could incorporate muscle imaging to further quantify potential muscle volume or structural changes.

Another limitation was that this study was a cross-sectional study, evaluating changes within individuals who previously received BoNT injections versus those who did not. Therefore,

we can not determine casuality between BoNT injections and increased muscle or joint stiffness. To do so a longitudinal, randomized, control study could be conducted in the future to study longitudinal changes to deduce any causal or dosage dependent effects of BoNT.

6 SUMMARY

To the best of our knowledge, the current study is the most thorough investigation of *in vivo* passive elastic torques at the hand in the chronic hemiparetic stroke population. Our findings indicate that, after stroke, motor impairment severity does not impact the passive torques about either the wrist or fingers, nor significantly limit passive extension at the fingers, unless an individual has received BoNT. This suggests the loss of hand function post-stroke is primarily due to weakness from voluntary activation deficits[6] and impaired control of the muscles of the hand[11] following disruptions of corticofugal pathways.[51,52] Future rehabilitation techniques should therefore focus on motor deficits post stroke to achieve improved hand function. Additionally, the potential adverse effects of BoNT that our data highlights should be explored to determine if the positive effects of reduced muscle hypertonicity and spasticity outweigh potential negative side effects of increased muscle stiffness to maximize recovery of individuals following a hemiparetic stroke.

7 ACKNOWLEDGEMENTS

We especially want to thank Dr. Arno Stienen and Paul Krueger for their assistance with the custom device design and modification, and Vikram Darbhe for his assistance in experimental set-up and data collection

8 FUNDING SOURCES

This work was supported by a Promotion of Doctoral Studies Level II Scholarship from the Foundation for Physical Therapy, American Heart Association Pre-Doctoral Fellowship: 16PRE30970010, National Institutes of Health (NIH) (T32EB009406) to J.P.A.D., and NIH Grant R01HD084009 to J.P.A.D. and W.M.M..

9 DISCLOSURES

Disclosures: None

1. Baker SN, Zaaimi B, Fisher KM, Edgley SA, Soteropoulos DS. Pathways mediating functional recovery. *Prog Brain Res.* 2015;218:389-412.
2. Zaaimi B, Edgley SA, Soteropoulos DS, Baker SN. Changes in descending motor pathway connectivity after corticospinal tract lesion in macaque monkey. *Brain.* 2012;135(Pt 7):2277-2289.
3. Ellis MD, Drogos J, Carmona C, Keller T, Dewald JP. Neck rotation modulates flexion synergy torques, indicating an ipsilateral reticulospinal source for impairment in stroke. *J Neurophysiol.* 2012;108(11):3096-3104.
4. McPherson JG, Chen A, Ellis MD, Yao J, Heckman CJ, Dewald JPA. Progressive recruitment of contralesional cortico-reticulospinal pathways drives motor impairment post stroke. *J Physiol.* 2018;596(7):1211-1225.
5. Karbasforoushan H, Cohen-Adad J, Dewald JPA. Brainstem and spinal cord MRI identifies altered sensorimotor pathways post-stroke. *Nat Commun.* 2019;10(1):3524.
6. Hoffmann G, Conrad MO, Qiu D, Kamper DG. Contributions of voluntary activation deficits to hand weakness after stroke. *Top Stroke Rehabil.* 2016;23(6):384-392.
7. Kamper DG, Fischer HC, Cruz EG, Rymer WZ. Weakness is the primary contributor to finger impairment in chronic stroke. *Arch Phys Med Rehabil.* 2006;87(9):1262-1269.
8. Kamper DG, Harvey RL, Suresh S, Rymer WZ. Relative contributions of neural mechanisms versus muscle mechanics in promoting finger extension deficits following stroke. *Muscle Nerve.* 2003;28(3):309-318.
9. Dewald JP, Pope PS, Given JD, Buchanan TS, Rymer WZ. Abnormal muscle coactivation patterns during isometric torque generation at the elbow and shoulder in hemiparetic subjects. *Brain.* 1995;118 (Pt 2):495-510.
10. Dewald JP, Sheshadri V, Dawson ML, Beer RF. Upper-limb discoordination in hemiparetic stroke: implications for neurorehabilitation. *Top Stroke Rehabil.* 2001;8(1):1-12.
11. Miller LC, Dewald JP. Involuntary paretic wrist/finger flexion forces and EMG increase with shoulder abduction load in individuals with chronic stroke. *Clin Neurophysiol.* 2012;123(6):1216-1225.
12. Sukal TM, Ellis MD, Dewald JP. Shoulder abduction-induced reductions in reaching work area following hemiparetic stroke: neuroscientific implications. *Exp Brain Res.* 2007;183(2):215-223.
13. Brunnstrom S. *Movement therapy in hemiplegia: a neurophysiological approach.* 1st ed. New York,: Medical Dept.; 1970.
14. Kamper DG, Rymer WZ. Quantitative features of the stretch response of extrinsic finger muscles in hemiparetic stroke. *Muscle Nerve.* 2000;23(6):954-961.
15. McPherson JG, Ellis MD, Heckman CJ, Dewald JP. Evidence for increased activation of persistent inward currents in individuals with chronic hemiparetic stroke. *J Neurophysiol.* 2008;100(6):3236-3243.
16. McPherson JG, Stienen AH, Drogos JM, Dewald JP. Modification of Spastic Stretch Reflexes at the Elbow by Flexion Synergy Expression in Individuals With Chronic Hemiparetic Stroke. *Arch Phys Med Rehabil.* 2017.
17. Bhadane MY, Gao F, Francisco GE, Zhou P, Li S. Correlation of Resting Elbow Angle with Spasticity in Chronic Stroke Survivors. *Frontiers in neurology.* 2015;6:183.

18. O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. *Brain.* 1996;119 (Pt 5):1737-1749.
19. Lee JM, Gracies JM, Park SB, Lee KH, Lee JY, Shin JH. Botulinum Toxin Injections and Electrical Stimulation for Spastic Paresis Improve Active Hand Function Following Stroke. *Toxins (Basel).* 2018;10(11).
20. Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. *Eur J Phys Rehabil Med.* 2017;53(2):256-267.
21. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2016;86(19):1818-1826.
22. Minamoto VB, Suzuki KP, Bremner SN, Lieber RL, Ward SR. Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections. *Muscle Nerve.* 2015;52(4):649-657.
23. Ward SR, Minamoto VB, Suzuki KP, Hulst JB, Bremner SN, Lieber RL. Recovery of rat muscle size but not function more than 1 year after a single botulinum toxin injection. *Muscle Nerve.* 2017.
24. Ates F, Yucesoy CA. Effects of botulinum toxin type A on non-injected bi-articular muscle include a narrower length range of force exertion and increased passive force. *Muscle Nerve.* 2014;49(6):866-878.
25. Yucesoy CA, Ates F. BTX-A has notable effects contradicting some treatment aims in the rat triceps surae compartment, which are not confined to the muscles injected. *J Biomech.* 2018;66:78-85.
26. Thacker BE, Tomiya A, Hulst JB, et al. Passive mechanical properties and related proteins change with botulinum neurotoxin A injection of normal skeletal muscle. *J Orthop Res.* 2012;30(3):497-502.
27. Gao F, Grant TH, Roth EJ, Zhang LQ. Changes in passive mechanical properties of the gastrocnemius muscle at the muscle fascicle and joint levels in stroke survivors. *Arch Phys Med Rehabil.* 2009;90(5):819-826.
28. Kwah LK, Herbert RD, Harvey LA, et al. Passive mechanical properties of gastrocnemius muscles of people with ankle contracture after stroke. *Arch Phys Med Rehabil.* 2012;93(7):1185-1190.
29. Nelson CM, Murray WM, Dewald JPA. Motor Impairment-Related Alterations in Biceps and Triceps Brachii Fascicle Lengths in Chronic Hemiparetic Stroke. *Neurorehabil Neural Repair.* 2018;32(9):799-809.
30. Given JD, Dewald JP, Rymer WZ. Joint dependent passive stiffness in paretic and contralateral limbs of spastic patients with hemiparetic stroke. *J Neurol Neurosurg Psychiatry.* 1995;59(3):271-279.
31. Mirbagheri MM, Alibiglou L, Thajchayapong M, Rymer WZ. Muscle and reflex changes with varying joint angle in hemiparetic stroke. *J Neuroeng Rehabil.* 2008;5:6.
32. Eby S, Zhao H, Song P, et al. Quantitative Evaluation of Passive Muscle Stiffness in Chronic Stroke. *Am J Phys Med Rehabil.* 2016;95(12):899-910.

33. de Gooijer-van de Groep KL, de Vlugt E, van der Krogt HJ, et al. Estimation of tissue stiffness, reflex activity, optimal muscle length and slack length in stroke patients using an electromyography driven antagonistic wrist model. *Clin Biomech (Bristol, Avon).* 2016;35:93-101.
34. Sinkjaer T, Magnussen I. Passive, intrinsic and reflex-mediated stiffness in the ankle extensors of hemiparetic patients. *Brain.* 1994;117 (Pt 2):355-363.
35. Freire B, Dias CP, Goulart NB, et al. Achilles tendon morphology, plantar flexors torque and passive ankle stiffness in spastic hemiparetic stroke survivors. *Clin Biomech (Bristol, Avon).* 2017;41:72-76.
36. Schmit BD, Dewald JP, Rymer WZ. Stretch reflex adaptation in elbow flexors during repeated passive movements in unilateral brain-injured patients. *Arch Phys Med Rehabil.* 2000;81(3):269-278.
37. Lawrence ES, Coshall C, Dundas R, et al. Estimates of the prevalence of acute stroke impairments and disability in a multiethnic population. *Stroke.* 2001;32(6):1279-1284.
38. Broeks JG, Lankhorst GJ, Rumping K, Prevo AJ. The long-term outcome of arm function after stroke: results of a follow-up study. *Disabil Rehabil.* 1999;21(8):357-364.
39. Parker VM, Wade DT, Langton Hewer R. Loss of arm function after stroke: measurement, frequency, and recovery. *Int Rehabil Med.* 1986;8(2):69-73.
40. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS. Recovery of upper extremity function in stroke patients: the Copenhagen Stroke Study. *Arch Phys Med Rehabil.* 1994;75(4):394-398.
41. Gowland C, Stratford P, Ward M, et al. Measuring physical impairment and disability with the Chedoke-McMaster Stroke Assessment. *Stroke.* 1993;24(1):58-63.
42. Stienen A, Moulton TS, Miller LC, Dewald JPA. Wrist and Finger Torque Sensor for the Quantification of Upper Limb Motor Impairments Following Brain Injury. Paper presented at: 2011 IEEE International Conference on Rehabilitation Robotics2011; Zurich , Switzerland.
43. Fraigne JJ, Torontali ZA, Snow MB, Peever JH. REM Sleep at its Core - Circuits, Neurotransmitters, and Pathophysiology. *Frontiers in neurology.* 2015;6:123.
44. Krenzer M, Anaclet C, Vetrivelan R, et al. Brainstem and spinal cord circuitry regulating REM sleep and muscle atonia. *PLoS One.* 2011;6(10):e24998.
45. Hodes R, Dement WC. Depression of Electrically Induced Reflexes ("H-Reflexes") in Man during Low Voltage Eeg "Sleep". *Electroencephalogr Clin Neurophysiol.* 1964;17:617-629.
46. Liu F, Tang W, Chen D, et al. Expression of TGF-beta1 and CTGF Is Associated with Fibrosis of Denervated Sternocleidomastoid Muscles in Mice. *Tohoku J Exp Med.* 2016;238(1):49-56.
47. Russo TL, Peviani SM, Durigan JL, Salvini TF. Electrical stimulation increases matrix metalloproteinase-2 gene expression but does not change its activity in denervated rat muscle. *Muscle Nerve.* 2008;37(5):593-600.
48. Faturi FM, Franco RC, Gigo-Benato D, et al. Intermittent stretching induces fibrosis in denervated rat muscle. *Muscle Nerve.* 2016;53(1):118-126.

49. Nikolaou S, Liangjun H, Tuttle LJ, et al. Contribution of denervated muscle to contractures after neonatal brachial plexus injury: not just muscle fibrosis. *Muscle Nerve.* 2014;49(3):398-404.
50. Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. *Toxicon.* 2015;107(Pt A):64-67.
51. Kuypers HG. The Descending Pathways to the Spinal Cord, Their Anatomy and Function. *Prog Brain Res.* 1964;11:178-202.
52. Lawrence DG, Kuypers HG. The functional organization of the motor system in the monkey. I. The effects of bilateral pyramidal lesions. *Brain.* 1968;91(1):1-14.

Table 1: Table of Inclusion/Exclusion Criteria for Participants

Subject Inclusion Criteria
Stroke occurred at least one year prior to participation in the study
Paralysis confined to one side of the body
Ability to give informed consent

Subject Exclusion Criteria
Stroke occurred in the cerebellum or brainstem
Impairment or injury in the unimpaired limb
Severe atrophy of the impaired limb
Severe concurrent medical problems

Table 2: Subject Demographics.
(CMHS – Chedoke McMaster Stroke Assessment Hand Score, MAS – Modified Ashworth Scale)

Impairment Level	Sex	Age in years (SD)	Time Since Stroke in years (SD)	Age at time of stroke in years (SD)	Paretic Side	CMHS	MAS	Time Since Last BoNT Injection in years (SD)
BoNT-Injected Severe (n=7)	6-M, 1-F	56.7 (8.3)	10.7 (5.3)	46.0 (5.1)	4-L,3-R	2.85 (0.38)	2.71 (0.48)	4.5 (2.8)
No-BoNT Severe (n=9)	6-M, 3-F	60.28 (10.40)	17.1 (7.91)	43.2 (13.6)	5-L, 4-R	2.44 (0.73)	2.17 (0.87)	n/a
Moderate (n=9)	5-M, 4-F	64.3 (7.95)	13.2 (7.96)	51.1 (12.5)	6-L, 3-R	4.22 (0.44)	1.78 (0.94)	n/a
Mild (n=9)	5-M, 4-F	56.93 (12.18)	8.41 (3.71)	48.5 (9.8)	1-L, 8-R	6.44 (0.53)	0.28 (0.57)	n/a



Figure 1: Image of experimental set up with participant seated upright and hand secured within the custom built device, positioned so the effect of gravity is eliminated at both the wrist and metacarpophalangeal (MCP). Distal finger joints were splinted within the device to prevent movement. Muscle activity was monitored throughout trials using surface EMGs electrodes placed over 4 muscles: Extensor Digitorium Communis and Extensor Carpi Radialis electrodes are visible, electrodes for the Flexor Digitorium Superficialis and Flexor Carpi Ulnaris on anterior forearm are not visible.



Figure 2: Average metacarpophalangeal (MCP) torques measured in the paretic (red) and non-paretic (blue) limb over MCP joint range of motion for the (a) BoNT-injected, and no-BoNT severely, moderately, and (d) mildly impaired groups. Wrist posture was locked in -60 (left), 0 (middle), and 60 degrees flexion (right). Negative angles and torques indicate extension and positive flexion. At any combination of wrist and MCP postures, data are only displayed if $n \geq 3$. Significant differences (*denotes $p<0.05$) in torques measured in paretic vs non-paretic limbs were observed in every group. Average interlimb difference (b) in MCP torques (paretic torques minus non-paretic torques) for each group at each locked wrist posture. Torque differences were significantly greater in the BoNT group, but there was a significant interaction with wrist posture ($p<0.05$). Brackets denote significant differences ($p<0.05$) at a specific wrist posture. Error bars indicate one standard error.



Figure 3: Average wrist torques measured in the paretic (red) and non-paretic (blue) limb over the wrist's range of motion for the (a) BoNT-injected, and no-BoNT severely, moderately, and mildly impaired groups. Metacarpophalangeal (MCP) posture was locked in -60 (left), 0 (middle), and 75 degrees flexion (right). Negative angles and torques indicate extension and positive flexion. At any combination of wrist and MCP postures, data are only displayed if $n \geq 3$. Significant differences (*denotes $p<0.05$) in torques measured in paretic vs non-paretic were observed. Average interlimb difference in (b) wrist torques (paretic torques minus non-paretic torques) for each group, at each locked MCP posture. Torque differences were significantly greater in the BoNT group, but there was a significant interaction with MCP posture ($p<0.05$). brackets denote significant differences ($p<0.05$) at a specific MCP postures. Error bars indicate one standard error.



Figure 4: Limits of the metacarpophalangeal (MCP) passive range of motion (ROM) in extension throughout the custom device's nine available wrist postures for the (a) BoNT-injected and (b) no-BoNT severe groups. All, but one BoNT-injected subject (limited to -15 degrees), could be positioned in all 9 wrist postures, limits of ROM for MCP presented are the average for the paretic (red) and non-paretic (blue) hands. MCP extension of the BoNT-injected paretic hand was significantly less than the non-paretic hand (*denotes $p < 0.001$ between paretic v non-paretic hands). Deficits in passive extension increased with wirst extension. No significant loss of passive MCP extension was observed in the no-BoNT group was observed. Error bars indicate one standard error.

Figure 1



Figure 2


a)
Total Finger Torque Data
BoNT*
Severe*
Moderate*
Mild*
-60
0
60
MCP Joint Torque (N/cm)
MCP Joint Angle (deg)
b)
Torque Difference (N/cm)
BoNT
Severe
Moderate
Mild

Figure 3


a)
Total Wrist Torque Data
BoNT*
b)
Severe*
c)
Moderate*
d)
Mild
-60
0
75
Wrist Joint Torque (N/cm)
Wrist Joint Angle (deg)
b)
Torque Difference (N/cm)
BoNT
Severe
Moderate
Mild

Figure 4


Extension End MCP Range-of-Motion Throughout Wrist Postures
a)
BoNT-injected Severe*
b)
No-BoNT Severe
Extension Limit of Device
Extension Limit of Device
Non-Paretic
Paretic
Wrist Joint Posture (deg)
Wrist Extension
Wrist Flexion
-60
-45
-30
-15
0
15
30
45
60
-80
-60
-40
-20
0
20
40
60
80
MCP Extension
MCP Flexion
MCP Extension
MCP Flexion
End Range MCP Joint Angle (deg)